Tissue microarray based analysis of prognostic markers in invasive bladder cancer: Much effort to no avail?

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 1, 2008, Pages 17-24

  Liedberg, Fredrik ^a   Anderson, Harald ^a   Chebil, Gunilla ^b   Gudjonsson, Sigurdur ^a   Höglund, Mattias ^a   Lindgren, David ^a   Lundberg, Lena Maria ^a   Lövgren, Kristina ^a   Fernö, Mårten ^a   Månsson, Wiking ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

Author keywords

Bladder cancer; Prognosis; Radical cystectomy; Tissue microarray

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; P21 ACTIVATED KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN RB1; RETINOBLASTOMA PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STAT1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN C;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SAMPLE SIZE; SURVIVAL ANALYSIS; SWEDEN; URINARY BLADDER NEOPLASMS;

EID: 37649024111     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.08.021     Document Type: Article

References (44)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 27 (2006) 361-373
3. Lindgren D, Liedberg F, Bendahl P-O, et al. Bladder carcinoma expression profiles associated with FGFR3/TP53 mutation status and a MHC class I gene signature that predicts lymph node metastasis and survival. [in press].
4. Shariat S.F., Tokunaga H., Zhou J., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22 (2004) 1014-1024
5. Chatterjee S.J., Datar R., Youssefzadeh D., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22 (2004) 1007-1013
6. Hemal A.K., Khaitan A., Dinda A.K., et al. Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy. Urol Int 70 (2003) 42-46
7. Jahnson S., and Karlsson M.G. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer 89 (2000) 619-629
8. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (1998) 844-847
9. Linke S.P., Bremer T.M., Herold C.D., et al. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res 12 (2006) 1175-1183
10. Resnick M.B., Routhier J., Konkin T., et al. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: A tissue microarray study. Clin Cancer Res 10 (2004) 3069-3075
11. Mitra A.P., Datar R.H., and Cote R.J. Molecular staging of bladder cancer. BJU Int 96 (2005) 7-12
12. Blanchet P., Droupy S., Eschwege P., et al. Prospective evaluation of Ki-67 labeling in predicting the recurrence and progression of superficial bladder transitional cell carcinoma. Eur Urol 40 (2001) 169-175
13. Kiyoshima K., Oda Y., Kinukawa N., et al. Overexpression of laminin-5 γ2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: Association with cyclooxygenase 2, epidermal growth factor, and human epidermal growth factor 2. Hum Pathol 36 (2005) 522-530
14. Clairotte A., Lascombe I., Fauconnet S., et al. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: Identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 125 (2006) 119-126
15. David O., Jett J., LeBeau H., et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10 (2004) 6865-6871
16. Panigrahi A.R., Pinder S.E., Chan S.Y., et al. The role of PTEN and its signaling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204 (2004) 93-100
17. Kamai T., Tsujii T., Arai K., et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9 (2003) 2632-2641
18. Suzuki K., Morita T., and Tokue A. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol 12 (2005) 152-158
19. Liukkonen T., Rajala P., Raitanen M., et al. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/pT1) bladder cancer: A prospective study. Eur Urol 36 (1999) 292-400
20. Gårdmark T., Wester K., de la Torre M., et al. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 95 (2005) 982-986
21. Mialhe A., Louis J., Montlevier S., et al. Expression of E-cadherin and alpha-, beta- and gamma-catenins in human bladder carcinomas: Are they good prognostic factors?. Invasion Metastasis 17 (1997) 124-137
22. Kalbfleish J.D., and Prentice R.L. The statistical analysis of failure time data. 2nd ed. (2002), Wiley, New York (NY)
23. Koksal I.T., Yasar D., Dirice E., et al. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Urol Int 75 (2005) 102-106
24. Rajjayabun P.H., Keegan P.E., Lunec J., et al. erbB receptor expression patterns in human bladder cancer. Urology 66 (2005) 196-200
25. Coogan C.L., Estrada C.R., Kapur S., et al. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63 (2004) 786-790
26. Tsai Y.S., Tzai T.S., Chow N.H., et al. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. Urol Int 71 (2003) 262-270
27. Kamai T., Kawakami S., Koga F., et al. RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer. BJU Int 91 (2003) 234-238
28. Nocito A., Bubendorf L., Tinner E.M., et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194 (2001) 349-357
29. Simon R., Richter J., Wagner U., et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 61 (2001) 4514-4519
30. Shergill I.S., Rao A.R., Anjum F.H., et al. Tissue microarrays and their relevance to the urologist. J Urol 175 (2006) 19-26
31. Rubin M.A., Dunn R., Strawderman M., et al. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26 (2002) 312-319
32. Dekairelle A.F., Tombal B., Cosyns J.P., et al. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Clin Cancer Res 11 (2005) 4724-4732
33. Aaboe M., Birkenkamp-Demtroder K., Wiuf C., et al. SOX4 expression in bladder carcinoma: Clinical aspects and in vitro functional characterization. Cancer Res 66 (2006) 3434-3442
34. Theodorescu D., Sapinoso L.M., Conaway M.R., et al. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 10 (2004) 3800-3806
35. Rao J., Seligson D., Visapaa H., et al. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer 95 (2002) 1247-1257
36. Zheng M., Simon R., Mirlacher M., et al. TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Am J Pathol 165 (2004) 63-69
37. Ohlsson G., Moreira J.M., Gromov P., et al. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 4 (2005) 570-581
38. Smith S.C., Oxford G., Wu Z., et al. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 66 (2006) 1917-1922
39. Wild P.J., Kunz-Schughart L.A., Stoehr R., et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol 27 (2005) 385-391
40. Kocher T., Zheng M., Bolli M., et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: A tissue microarray study. Int J Cancer 100 (2002) 702-705
41. Simon R., Atefy R., Wagner U., et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107 (2003) 764-772
42. Zaharieva B.M., Simon R., Diener P.A., et al. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 201 (2003) 603-608
43. Oeggerli M., Tomovska S., Schraml P., et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 23 (2004) 5616-5623
44. Richter J., Wagner U., Kononen J., et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 157 (2000) 787-794